105 results on '"Sieper, Joachim"'
Search Results
2. Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort
3. Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort.
4. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
5. Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results
6. Management of ankylosing spondylitis/axial spondyloarthritis
7. Contributors
8. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab
9. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial
10. Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results.
11. Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension
12. P193 Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis
13. Diagnosing axial spondyloarthritis: estimation of the disease probability in patients witha prioridifferent likelihoods of the diagnosis
14. Radiographic sacroiliitis progression in axial spondyloarthritis: central reading of 5 year follow-up data from the Assessment of SpondyloArthritis international Society cohort
15. Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility
16. Management of ankylosing spondylitis
17. Contributors
18. Evaluation of the spinal pain score in AS—a psychometric analysis
19. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial
20. Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension.
21. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome
22. 126 - Management of axial spondyloarthritis
23. Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis
24. Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis
25. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany
26. Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis.
27. Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?
28. 261 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the Phase 3 trial, MEASURE 2
29. 262 Secukinumab demonstrates rapid and sustained efficacy in ankylosing spondylitis patients with normal or elevated baseline C-reactive protein levels: pooled analysis of two Phase 3 studies
30. Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data
31. Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis
32. Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis.
33. 172 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2
34. 174 Secukinumab demonstrates consistent safety over long-term exposure up to three years in patients with active ankylosing spondylitis: pooled analysis of three Phase III trials
35. Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort
36. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?
37. Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach
38. 118 - Management of ankylosing spondylitis/axial spondyloarthritis
39. Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time
40. 114. SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)
41. New treatment targets for axial spondyloarthritis: Table 1
42. Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?
43. Contributors
44. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics
45. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?
46. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab
47. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial
48. I59. New Biologic Treatments for Ankylosing Spondylitis
49. 229. Relationship Between MRI AND Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis After Two Years of Adalimumab Therapy
50. 215. Sustained Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Two Years of Adalimumab Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.